EVOKE PHARMA, INC. AMENDMENT TO SERIES A COMMON STOCK PURCHASE WARRANT, SERIES B COMMON STOCK PURCHASE WARRANT AND SERIES C COMMON STOCK PURCHASE WARRANTCommon Stock Purchase Warrant • June 20th, 2024 • Evoke Pharma Inc • Pharmaceutical preparations
This Amendment (this “Amendment”) is made as of [ ], 2024 by and between Evoke Pharma, Inc., a Delaware corporation (the “Company”), and _____________________ (the “Holder”), and constitutes an amendment to that certain Series A Common Stock Purchase Warrant (Warrant No.: A-[ ]), issued by the Company on February 13, 2024 (the “Series A Warrant”), an amendment to that certain Series B Common Stock Purchase Warrant (Warrant No.: B-[ ]), issued by the Company on February 13, 2024 (the “Series B Warrant”) and an amendment to that certain Series C Common Stock Purchase Warrant (Warrant No.: C-[ ]), issued by the Company on February 13, 2024 (the “Series C Warrant”). Capitalized terms used but not otherwise defined in this Amendment shall have the meanings given to such terms in the Series B Warrant or the Series C Warrant, as applicable.
